Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Artivion, Inc. before investing.

In this article, we go over a few key elements for understanding Artivion, Inc.’s stock price such as:

• Artivion, Inc.’s current stock price and volume
• Why Artivion, Inc.’s stock price changed recently
• Upgrades and downgrades for AORT from analysts
• AORT’s stock price momentum as measured by its relative strength

About Artivion, Inc. (AORT)

Before we jump into Artivion, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Want to learn more about Artivion, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Artivion, Inc..

Artivion, Inc.’s Stock Price as of Market Close

As of June 12, 2026, 4:00 PM, CST, Artivion, Inc.’s stock price was $20.100.

Artivion, Inc. is down 2.43% from its previous closing price of $20.600.

During the last market session, Artivion, Inc.’s stock traded between $20.010 and $20.810. Currently, there are approximately 48.07 million shares outstanding for Artivion, Inc..

Artivion, Inc.’s price-earnings (P/E) ratio is currently at 83.4, which is high compared to the Health Care Equipment & Supplies industry median of 26.2. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Artivion, Inc. Stock Price History

Artivion, Inc.’s (AORT) price is currently down 9.42% so far this month.

During the month of June, Artivion, Inc.’s stock price has reached a high of $22.630 and a low of $19.820.

Over the last year, Artivion, Inc. has hit prices as high as $48.250 and as low as $19.160. Year to date, Artivion, Inc.’s stock is down 55.93%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Artivion, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 12, 2026, there were 0 analysts who downgraded Artivion, Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Artivion, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Artivion, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Artivion, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Artivion, Inc. (AORT) by visiting AAII Stock Evaluator.

Relative Price Strength of Artivion, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 12, 2026, Artivion, Inc. has a weighted four-quarter relative price strength of -16.30%, which translates to a Momentum Score of 15 and is considered to be Very Weak.

Want to learn more about how Artivion, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Artivion, Inc. Stock Price: Bottom Line

As of June 12, 2026, Artivion, Inc.’s stock price is $20.100, which is down 2.43% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Artivion, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.